| AMAG shares rise on strong revenue outlook for anemia drug - Reuters |
|
|
Reuters"We expect long-term Feraheme growth to be driven by the non-dialysis setting, which offers a faster sales cycle and no exposure to the pending bundled ...AMAG Pharmaceuticals Announces Preliminary Feraheme® Fourth Quarter 2009 Net ... read more |